skip to main content
News and Events


Here are the latest TFRI news stories. See our archive for a full history of news.

  • October 26, 2017

    The B.C. Lung Screen Trial at Vancouver General Hospital is currently recruiting 2,000 individuals from the Lower Mainland who are between 55 and 80 years of age, with at least a 30-pack-years smoking history to take part in a new research project.

  • October 18, 2017

    A pan-Canadian team of cancer researchers has developed a predictive model for detecting early-stage lung cancer in high-risk individuals with significantly greater accuracy than other leading models. This Terry Fox Research Institute study suggests the team’s innovative approach could be considered for use in lung cancer screening programs both in Canada and around the world.

  • September 18, 2017

    The annual Terry Fox Research Institute Ontario Node Symposium is just around the corner, and will be held on Dec. 4, 2017 at at the the MaRS Discovery Centre in Toronto.

  • September 06, 2017

    A new study has analyzed hundreds of sequenced medulloblastoma (MB) samples, identifying new targets that could give children with this disease less harmful therapeutic options.

  • September 06, 2017

    A recent study by a prolific TFRI-funded team has demonstrated that disrupting ERG transcriptional activity is sufficient to suppress the major characteristics of ERG-transformed prostate cancers.

  • September 06, 2017

    Ontario cancer researchers have found that an oncolytic virus may lead to a promising new therapy option for patients with peritoneal carcinomatosis, a disseminated intra-abdominal tumour.

  • September 06, 2017

    Diffuse optical spectroscopic texture features can predict breast cancer response to neoadjuvant chemotherapy in locally advanced breast cancer patients before therapy even begins.

  • September 06, 2017

    A team of Canadian cancer researchers has shown that rare, therapy-resistant leukemia stem cells are already present at diagnosis in patients who experience relapses of acute myeloid leukemia (AML).

  • September 06, 2017

    While significant accolades are given to scientists who discover genetic mutations that are linked to cancer, it is equally important to determine factors that are not correlated.

  • September 06, 2017

    Subtype-specific alterations in a driver gene for non-Hodgkin lymphoma (BCL2) is strongly associated with poor patient outcomes after treatment.

Back to Top